The second coming of consumer genomics with 3 predictions for 2018
Several fundamentals have changed to accelerate growth in the genomics space, spurring our second look into the sector.
Several fundamentals have changed to accelerate growth in the genomics space, spurring our second look into the sector.
The rising levels of efficacy when using cancer immunotherapy - as well as the rising costs of patient treatments - are making this a lucrative field to Wall Street, a top executive at UBS says.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.